Company facts
- Headquarters
- Chicago, Illinois
- Most recent report
- 10-Q, filed Oct 23, 2026
- Incorporated
- Delaware
- Filings on record
- 1,011+ filings
- On EDGAR
- CIK 1156375
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 33
News 8 of 90
- 8-K Quarterly results Oct 21, 2026
- 8-K Current report on a material event Sep 25, 2026
- 8-K Leadership change Sep 9, 2026
- 8-K Current report on a material event Aug 11, 2026
- 8-K Quarterly results Jul 22, 2026
- 8-K Leadership change Jun 17, 2026
- 8-K Shareholder vote results Jun 10, 2026
- 8-K Shareholder vote results May 19, 2026
Prospectuses and Registrations 8 of 11
- S-8 Registration statement for an employee plan Mar 13, 2026
- 424B5 Prospectus supplement for an offering Mar 4, 2025
- FWP Free writing prospectus Mar 3, 2025
- 424B5 Prospectus supplement for an offering Mar 3, 2025
- S-3ASR Automatic shelf registration Mar 3, 2025
- S-8 Registration statement for an employee plan Jun 9, 2022
- 424B5 Prospectus supplement for an offering Mar 3, 2022
- FWP Free writing prospectus Mar 1, 2022
Proxies 8 of 41
- DEFA14A Extra proxy material May 19, 2026
- DEFA14A Extra proxy material Apr 16, 2026
- DEFA14A Extra proxy material Mar 23, 2026
- DEF 14A Proxy statement for a shareholder vote Mar 23, 2026
- DEFA14A Extra proxy material Mar 12, 2026
- PRE 14A Preliminary proxy statement Mar 12, 2026
- DEFA14A Extra proxy material Mar 25, 2025
- DEFA14A Extra proxy material Mar 20, 2025
Ownership 8 of 821
- 144 Notice of a proposed sale of restricted stock Nov 9, 2026
- 4 Insider reported a trade Nov 3, 2026
- 4 Insider reported a trade Nov 2, 2026
- 3 Insider reported their initial holding Nov 2, 2026
- 144 Notice of a proposed sale of restricted stock Nov 2, 2026
- 144 Notice of a proposed sale of restricted stock Nov 2, 2026
- 4 Insider reported a trade Oct 27, 2026
- 144 Notice of a proposed sale of restricted stock Oct 27, 2026
Other 8 of 15
- ARS Annual report sent to shareholders Mar 23, 2026
- UPLOAD Comment letter from SEC staff Dec 1, 2025
- CORRESP Reply to SEC staff Sep 25, 2025
- UPLOAD Comment letter from SEC staff Sep 12, 2025
- ARS Annual report sent to shareholders Mar 20, 2025
- CORRESP Reply to SEC staff Feb 27, 2025
- ARS Annual report sent to shareholders Mar 19, 2024
- ARS Annual report sent to shareholders Mar 20, 2023
What to read: Sep 2026 10-Q
SECSift found 2 of 11 sections worth reading, with 0 positive, 5 notable, and 2 negative flags.
Financial Statements (Item 1)
Financial statements with notes: debt, equity, cash flow, and litigation details.Management's Discussion (Item 2)
Strong revenue and volume growth across nearly all product lines, with key concentration disclosures.Notable
What changed: Sep 2026 vs. Jun 2026
About 4% of CME's Sep 2026 10-Q is new information. 10 paragraphs were added, 111 changed, and 19 removed. Below are the most important lines SECSift identified.
New
Changed
- Exhibit 101 reference updated from period ended June 30, 2026 to September 30, 2026.
- Exhibit 3.1 changed from Seventeenth Amended and Restated Bylaws to Fourth Amended and Restated Certificate of Incorporation, as amended.
- Exhibit 3.2 changed from Fourth Amended and Restated Certificate of Incorporation to Seventeenth Amended and Restated Bylaws.
- Shares surrendered for tax on vesting rose to 82,756 from 658 in the prior quarter.
- The share repurchase program was announced on Dec 5, 2024, replacing the prior Dec 6, 2023 date.
Everything here comes from CME Group Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour. SECSift analysis was completed on Oct 24, 2026, from the 10-Q for Sep 2026.